Provenge Should Be "Very Familiar" To CMS Now, Dendreon Says About NCA
This article was originally published in The Pink Sheet Daily
Executive Summary
Dendreon comments on CMS' announcement that it would open a national coverage analysis, saying it is not needed given the amount of information the company already has provided on its new prostate cancer vaccine.
You may also be interested in...
Provenge Tops 500 Scripts Since Approval; Most Local Medicare Contractors Will Cover Product
Dendreon gave an update on the launch of the prostate cancer vaccine during its earnings call on Aug. 3.
Provenge Tops 500 Scripts Since Approval; Most Local Medicare Contractors Will Cover Product
Dendreon gave an update on the launch of the prostate cancer vaccine during its earnings call on Aug. 3.
Is Provenge "Reasonable And Necessary"? CMS Analysis For Medicare Coverage Seeks To Find Out
The Centers for Medicare and Medicaid Services may consider setting formal parameters around Medicare coverage for Dendreon's ground-breaking prostate cancer vaccine Provenge next year.